myriad

custom search

REVERSED
Tech Center 1700 Chemical & Materials Engineering
1777 Ex Parte Burbank et al 11813472 - (D) McMANUS 103 Potomac Law Group, PLLC MENON, KRISHNAN S

Tech Center 2100 Computer Architecture and Software
2167 Ex Parte Kannan et al 13755664 - (D) ENGLE 102/103 Hewlett Packard Enterprise PHAM, MICHAEL

2194 Ex Parte Lee et al 12813635 - (D) STRAUSS 103 Hewlett Packard Enterprise MUDRICK, TIMOTHY A

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2433 Ex Parte CANNING et al 14092252 - (D) McNEILL 103 AMY PATTILLO IBM CORP (AP) ANDERSON, MICHAEL D

2461 Ex Parte Nosley 12308719 - (D) ANDERSON 103 Kunzler Law Group - Lenovo BEDNASH, JOSEPH A

Tech Center 2600 Communications
2646 Ex Parte Ahluwalia et al 13339022 - (D) BUSCH 103 LEYDIG VOIT & MAYER, LTD SHEDRICK, CHARLES TERRELL

2691 Ex Parte SAKAI 12466408 - (D) McCARTNEY 102 WOLF GREENFIELD & SACKS, P.C. YANG, KWANG-SU

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3753 Ex Parte Deng 12842821 - (D) STEPINA 103 MIDDLETON & REUTLINGER CAHILL, JESSICA MARIE

AFFIRMED-IN-PART
Tech Center 1600 Biotechnology and Organic Chemistry
1651 Ex Parte Bayer et al 13865321 - (D) POLLOCK 102/103 102/103 CARELLA, BYRNE, CECCHI, OLSTEIN, BRODY & AGNELLO ARIANI, KADE

1675 Ex Parte CANNON et al 12913174 - (D) GRIMES 112(2)/112(4)/102 101 MCTAVISH PATENT FIRM HA, JULIE

We agree with the Examiner that claim 1 is not patent-eligible subject matter. Claim 1 is directed to a peptide that is made up of a fragment of the naturally occurring matriptase protein. Thus, the Supreme Court opinion in Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013), is controlling. In Myriad, the Court considered claims directed to isolated DNA encoding the BRCA1 polypeptide and fragments of at least 15 nucleotides of that DNA. Id. at 2113.

The Court held that “Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.” Id. at 2117. “Myriad found the location of the BRCA1 and BRCA2 genes, but that discovery, by itself, does not render the BRCA genes ‘new . . . composition[s] of matter,’ § 101, that are patent eligible.” Id. “Nor are Myriad’s claims saved by the fact that isolating DNA from the human genome severs chemical bonds and thereby creates a nonnaturally occurring molecule.” Id. at 2118.

Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. _, 133 S. Ct. 2107, 106 USPQ2d 1972 (2013) 2103 , 2106

Tech Center 2600 Communications
2696 Ex Parte Jiang 13726523 - (D) DEJMEK 103 103 PEIGEN JIANG JANSEN II, MICHAEL J

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2872 Ex Parte Broadway et al 12923838 - (D) MOORE 102 102/103 NIXON & VANDERHYE, PC MADONNA, JEFFREY E

AFFIRMED
Tech Center 1600 Biotechnology and Organic Chemistry
1615 Ex Parte Eloy et al 14006745 - (D) FLAX 103 BUCHANAN, INGERSOLL & ROONEY PC TCHERKASSKAYA, OLGA V

1629 Ex Parte BENATAR et al 13442213 - (D) MILLS 103 THE FIRM OF HUESCHEN AND SAGE FINN, MEGHAN R

1651 Ex Parte Walker 13399960 - (D) FLAX 102 103 Foley & Lardner LLP Kythera Biopharmaceuticals, Inc. FAN, LYNN Y

Tech Center 1700 Chemical & Materials Engineering
1726 Ex Parte Schimmele et al 13318523 - (D) GUEST 103 IP GROUP OF DLA PIPER LLP (US) CONLEY, OI K

2169 Ex Parte Lipson et al 12975192 - (D) MOORE 103 KILPATRICK TOWNSEND & STOCKTON LLP KIM, PAUL

Tech Center 2600 Communications
2625 Ex Parte Taylor 12350857 - (D) MOORE 103 MORRISS OBRYANT COMPAGNI, P.C. OKEBATO, SAHLU

2694 Ex Parte Rogoza 12193314 - (D) ENGELS 103 DALY, CROWLEY, MOFFORD & DURKEE, LLP RAYTHEON COMPANY HUGHES, EBONIN

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2883 Ex Parte Bradea et al 13206157 - (D) KENNEDY 102 CORNING INCORPORATED ROJAS, OMAR R

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3777 Ex Parte Henning et al 13486188 - (D) BAHR 103 SCHIFF HARDIN, LLP BRUTUS, JOEL F

chakrabarty, hartranft, myriad

custom search

REVERSED
Tech Center 1600 Biotechnology and Organic Chemistry
1654 Ex Parte Burkhard 10545676 - (D) PRATS 112(1)/102 WENDEROTH, LIND & PONACK, L.L.P. HA, JULIE

Tech Center 1700 Chemical & Materials Engineering
1734 Ex Parte Legario et al 10646930 - (D) Per Curiam 103 BERESKIN & PARR LLP/S.E.N.C.R.L., s.r.l. FELTON, AILEEN BAKER

Tech Center 2100 Computer Architecture and Software
2177 Ex Parte Merkel et al 10335110 - (D) DIXON 103 SAP / FINNEGAN, HENDERSON LLP RUTLEDGE, AMELIA L

Tech Center 2400 Networking, Multiplexing, Cable, and Security
2443 Ex Parte Kihara et al 10861212 - (D) DIXON 103 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP SHIN, KYUNG H

2476 Ex Parte CARDONA et al 11751302 - (D) CLEMENTS 103 IBM CORPORATION (MH) c/o MITCH HARRIS, ATTORNEY AT LAW, L.L.C. SLOMS, NICHOLAS

2675 Ex Parte Beretta 11017012 - (D) RUGGIERO 103 HEWLETT-PACKARD COMPANY MENBERU, BENIYAM

Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3652 Ex Parte Kurita et al 11926720 - (D) BROWN 103 Applied Materials, Inc. LOWE, MICHAEL S

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3736 Ex Parte Calderon et al 12264293 - (D) FRANKLIN 103 DEKEL PATENT LTD. NGUYEN, HUONG Q

3736 Ex Parte Tenerz et al 10390185 - (D) NEW 103 FOLEY AND LARDNER LLP SMITH, FANGEMONIQUE A

3738 Ex Parte HARRIS et al 11626608 - (D) MILLS 102/103 Massachusetts General Hospital Perkins Cole LLP The General Hospital Corporation STEWART, JASON-DENNIS NEILKEN

3778 Ex Parte Cohen et al 11540418 - (D) HOFFMANN 102 KIMBERLY-CLARK WORLDWIDE, INC. ANDERSON, CATHARINE L

AFFIRMED-IN-PART
Tech Center 1600 Biotechnology and Organic Chemistry
1629 Ex Parte Miura et al 12067722 - (D) PRATS 103 103 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. TOWNSLEY, SARA ELIZABETH

AFFIRMED
Tech Center 1600 Biotechnology and Organic Chemistry
1629 Ex Parte Koenen et al 10515896 - (D) NEW 103 NATH, GOLDBERG & MEYER HUANG, GIGI GEORGIANA

Tech Center 1700 Chemical & Materials Engineering
1746 Ex Parte Reynolds et al 10363279 - (D) GARRIS 101/103 E I du Pont de Nemours & Company SCHATZ, CHRISTOPHER T

Tech Center 2100 Computer Architecture and Software
2113 Ex Parte Anerousis et al 10929878 - (D) HUME 102 RYAN, MASON & LEWIS, LLP MASKULINSKI, MICHAELC

2194 Ex Parte Cutlip 11847298 - (D) KUMAR 101/103 CAREY, RODRIGUEZ, GREENBERG & O'KEEFE, LLP TRUONG, LECHI

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3727 Ex Parte Mazur 11769810 - (D) BUNTING 103 Brinks Hofer Gilson & Lione/Ann Arbor SHAKERI, HADI

3769 Ex Parte Jung et al 11804304 - (D) PRATS 101/102/103 THE INVENTION SCIENCE FUND YAO, SAMCHUAN CUA  

REHEARING  

GRANTED
Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3763 Ex Parte Beckham 11551339 - (D) GREEN obviousness-type double patenting Bard Peripheral Vascular, Inc. FLICK, JASON E

REEXAMINATION

AFFIRMED
Tech Center 1700 Chemical & Materials Engineering
1732 THE HAARTZ CORPORATION Requester and Respondent v. BENECKE-KALIKO AG Patent Owner and Appellant 95000611 6,663,738 09/829,196 LEBOVITZ 102/103 FAY SHARPE LLP Third Party Requester: GROSSMAN,TUCKER,PERREAULT & PFLEGER, PLLC DIAMOND, ALAN D original TENTONI, LEO B

1745 The Gillette Company Patent Owner and Appellant 90010769 6410187 09/393,043 LEBOVITZ 103 FISH & RICHARDSON P.C. Third Party Requester: Stites & Harbison PLLC original THE PROCTER & GAMBLE COMPANY LOPEZ, CARLOS N original CREPEAU, JONATHAN

FEDERAL CIRCUIT

REHEARING  

GRANTED
Tech Center 3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3642 SOVERAIN SOFTWARE LLC, Plaintiff-Appellee, v. NEWEGG INC., Defendant-Appellant. 2011-1009 5,715,314 08/328,133 PER CURIAM claim interpretation STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. GREGORY, BERNARR E

SUPREME COURT  

AFFIRMED-IN-PART
Tech Center 1600 Biotechnology and Organic Chemistry
1632 ASSOCIATION FOR MOLECULAR PATHOLOGY, ET AL., PETITIONERS v. MYRIAD GENETICS, INC., ET AL. 12–398 5,747,282 08/483,554 5,693,473 08/480,784 5,837,492 08/639,501 THOMAS 101 101 ROTHWELL, FIGG, ERNST & MANBECK, P.C. RAZZAQUE, ABDUR; REES, DIANE; HAUDA, KAREN MARIE

This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U. S. 303, 309 (1980) (Products of nature are not created, and “‘manifestations . . . of nature [are] free to all men and reserved exclusively to none’”)....

In Chakrabarty, scientists added four plasmids to a bacterium, which enabled it to break down various components of crude oil. 447 U. S., at 305, and n. 1. The Court held that the modified bacterium was patentable. It explained that the patent claim was “not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter—a product of human ingenuity ‘having a distinctive name, character [and] use.’” Id. , at 309–310 (quoting Hartranft v. Wiegmann, 121 U. S. 609, 615 (1887); alteration in original).

Diamond v. Chakrabarty, 447 U.S. 303, 206 USPQ 193 (1980) , 2103, 2105, 2106, 2107.01

We merely hold that genes and the information they encode are not patent eligible under §101 simply because they have been isolated from the surrounding genetic material.